All In Biotech

Drug Trial Radar · NCT07745361

Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

MODeFIRe-1 (Molecular Degrader for Inhibitor Resistance): A Phase 2, Open-Label, Multicenter Study of Oral MRT-2359 in Combination With Apalutamide in Patients With Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Aug 18, 2026

Primary completion

Oct 2027

Study completion Apr 2028

Sponsor

Lead sponsor
Monte Rosa Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Aug 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study is to assess whether this treatment combination can lower prostate-specific antigen (PSA) The study will also evaluate the safety and tolerability of the treatment combination and assess additional measures of anti-tumor activity.

Conditions

  • Castration-Resistant Prostate Cancer (CRPC)
  • Castration-Resistant Prostate Cancer
  • Prostate Cancer
  • Prostate Cancer (Adenocarcinoma)

Interventions

  • Oral MRT-2359Drug

    Orally administered tablets of MRT-2359

  • ApalutamideDrug

    Orally administered apalutamide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the efficacy of MRT-2359 combined with apalutamideTime frame: 14 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • START Los Angeles

    Los Angeles, California · Recruiting

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California · Not yet recruiting

  • Rocky Mountain Cancer Center

    Colorado Springs, Colorado · Not yet recruiting

  • Kansas University Cancer Center

    Kansas City, Kansas · Not yet recruiting

  • University of Maryland Greenebaum Cancer Center

    Baltimore, Maryland · Not yet recruiting

  • Henry Ford

    Novi, Michigan · Not yet recruiting

  • XCancer Omaha

    Omaha, Nebraska · Recruiting

  • START New Jersey

    East Brunswick, New Jersey · Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Not yet recruiting

  • Lancaster Urology

    Lancaster, Pennsylvania · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Not yet recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • University of Washington Medical Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.